Keyphrases
Aldosterone Antagonists
14%
Cardiac Function
14%
Clinical Trials
100%
Composite Endpoint
14%
Design Futures
100%
Drug Adherence
14%
Drug Treatment
14%
Event Rate
14%
Heart Failure
14%
Heart Failure Hospitalization
14%
Heart Failure with Preserved Ejection Fraction (HFpEF)
100%
Mineralocorticoid Receptor Antagonists
14%
Overall Design
14%
Patient Profile
14%
Patient Selection
14%
Patients with Chronic Heart Failure
14%
Patients with Heart Failure
14%
Potential Gains
14%
Regional Heterogeneity
14%
Regional Variation
14%
Registry-based Randomized Controlled Trials
14%
Risk Reduction
14%
Spironolactone
28%
TOPCAT
100%
Treatment Effect
14%
Medicine and Dentistry
Aldosterone Antagonist
14%
Clinical Trial
100%
Congestive Heart Failure
42%
Drug Therapy
14%
Heart Failure with Preserved Ejection Fraction
100%
Heart Function
14%
Medication Compliance
14%
Mineralocorticoid Antagonist
14%
Spironolactone
28%
Treatment Effect
14%
Pharmacology, Toxicology and Pharmaceutical Science
Aldosterone Antagonist
14%
Clinical Trial
100%
Congestive Heart Failure
42%
Heart Failure with Preserved Ejection Fraction
100%
Mineralocorticoid Antagonist
14%
Spironolactone
28%
Biochemistry, Genetics and Molecular Biology
Aldosterone
14%
Clinical Trial
100%
Heart Ejection Fraction
100%
Heart Function
14%
Medication Compliance
14%
Mineralocorticoid Receptor
14%
Receptor Antagonist
14%
Spironolactone
28%